source
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
- AI researcher Kyunghyun Cho leaves Genentech to explore pharma applications at Endpoints AI DayKyunghyun Cho, a noted AI researcher, announced that he has left Genentech to pursue independent work in pharmaceutical applications of machine learning. He will discuss his new focus at Endpoints…